论文部分内容阅读
目的探讨乳腺癌功能磁共振表现与中医辨证分型之间的关系。方法 40例病理证实为乳腺癌患者,根据辨证分为肝郁痰凝、冲任失调、正虚毒炽三型,单次乳腺磁共振成像(MRI)中,结合T1W动态增强扫描序列与T2W首次通过灌注成像序列,对于各证型的MRI征象与证型的关系进行分析比较。结果乳腺癌肝郁痰凝与正虚毒炽证型之间T1W最大增强斜率、T1W病灶早期强化率、T2W早期信号丢失率差异均有统计学意义(P值分别为0.000,0.024,0.016);乳腺癌肝郁痰凝与冲任失调证型之间T1W最大增强斜率、T1W病灶早期强化率、T2W早期信号丢失率差异无统计学意义(P值分别为0.152,0.221,0.451);乳腺癌冲任失调与正虚毒炽证型之间T1W最大增强斜率、T1W病灶早期强化率、T2W早期信号丢失率差异均有统计学意义(P值分别为0.016,0.045,0.049)。结论乳腺功能MRI技术能提供给临床多个血流动力学参数,与乳腺癌中医证型存在的一定的相关性,有助于指导临床,可以作为乳腺癌分型诊断的参考依据之一。
Objective To explore the relationship between the functional magnetic resonance imaging of breast cancer and TCM syndrome differentiation. Methods Forty patients with pathologically confirmed breast cancer were divided into two groups according to syndrome differentiation: liver phlegm and blood stasis, Chong Chong Ren Tiao, Zhengxu Duixue three types. In a single breast magnetic resonance imaging (MRI), combined with T1W dynamic enhanced scan sequence and T2W for the first time Through the perfusion imaging sequence, the relationship between MRI signs and syndrome types of each syndrome was analyzed and compared. Results There were significant differences in T1W maximal enhancement slope, T1W lesion early enhancement rate, and T2W early signal loss rate between breast cancer liver qi stagnation and Zhengxu Duxue syndrome (P values were 0.000, 0.024, and 0.016, respectively). There was no significant difference in T1W maximal enhancement slope, T1W lesion early enhancement rate, and T2W early signal loss rate between breast cancer liver stagnation and malignancy (P = 0.152, 0.221, 0.451, respectively); The differences in T1W maximal enhancement slope, T1W lesion early enhancement rate, and T2W early signal loss rate between Renzheng and Zhengxu Zhengchi were statistically significant (P=0.016, 0.045, and 0.049, respectively). Conclusion The breast function MRI technology can provide multiple hemodynamic parameters in clinic, and it has a certain correlation with the TCM syndrome type of breast cancer. It can help guide the clinic and can be used as a reference for the diagnosis of breast cancer.